Facebook tracking pixel
G20
ICD-10-CM
Parkinson's Disease with Dementia

Find information on Parkinson's Disease with Dementia including clinical documentation, medical coding, and healthcare resources. Learn about diagnosis criteria, ICD-10 codes (G20, F02.81), DSM-5 criteria, and cognitive assessment for Parkinson's dementia. Explore resources for healthcare professionals on managing and documenting Parkinson's Disease dementia, including Lewy body dementia differentiation and dementia with Lewy bodies. This resource offers support for accurate clinical documentation and appropriate medical coding for Parkinson's disease dementia.

Also known as

Parkinson's Disease Dementia
PDD

Diagnosis Snapshot

Key Facts
  • Definition : Progressive neurodegenerative disorder marked by tremor, rigidity, slow movement, and cognitive decline.
  • Clinical Signs : Tremor, slow movement (bradykinesia), stiff muscles, impaired balance, memory loss, executive dysfunction.
  • Common Settings : Neurology clinics, movement disorder centers, geriatric care facilities, in-home care.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC G20 Coding
G20-G26

Extrapyramidal and movement disorders

Includes Parkinson's disease with or without dementia.

F02

Dementia in other diseases

Covers dementia specifically due to other conditions like Parkinson's.

G31.83

Mild cognitive impairment due to Parkinson's disease

Specifies mild cognitive decline related to Parkinson's, a precursor to dementia.

Documentation Best Practices

Documentation Checklist
  • Parkinsons Disease Dementia diagnosis documentation
  • Document cognitive decline impacting daily activities
  • PD diagnosis precedes dementia onset by >1 year
  • Specify dementia type: Lewy Body or Parkinsons Disease Dementia
  • Rule out other dementia causes with appropriate testing

Mitigation Tips

Best Practices
  • Accurate ICD-10-CM G20 G31.83 coding for PDD improves data.
  • Detailed CDI of cognitive decline aids PDD diagnosis tracking.
  • Timely MDS assessments capture PDD severity for care planning.
  • Regular neuropsychological tests enhance PDD documentation.
  • Compliance with HIPAA safeguards PDD patient data privacy.

Clinical Decision Support

Checklist
  • 1. Verify dementia diagnosis (ICD-10: F02.x, G30, G31.84)
  • 2. Confirm Parkinsonian signs: bradykinesia, rigidity, tremor (ICD-10: G20)
  • 3. Assess cognitive decline impact on daily activities
  • 4. Rule out other dementia causes (e.g., drugs, delirium, depression)
  • 5. Document disease onset and progression for accurate coding (PDD vs. DLB)

Reimbursement and Quality Metrics

Impact Summary
  • Parkinsons Disease Dementia reimbursement hinges on accurate coding (G31.83) for optimal Medicare and private payer claims.
  • Coding quality directly impacts Case Mix Index (CMI) accuracy, influencing hospital reimbursement for PD Dementia.
  • Precise documentation and coding of PD Dementia severity affect risk adjustment models and quality reporting metrics.
  • Timely and accurate claims submission for G31.83 minimizes denials and improves revenue cycle management for hospitals.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Quick Tips

Practical Coding Tips
  • Code G31.83 first, then F02.81
  • Document cognitive decline AND motor symptoms
  • Specify dementia severity for accurate coding
  • Query physician if documentation unclear
  • Review PD-D diagnostic criteria regularly

Documentation Templates

Patient presents with a clinical diagnosis of Parkinson's Disease with Dementia (PDD).  The patient exhibits the characteristic motor symptoms of Parkinson's disease, including bradykinesia, resting tremor, rigidity, and postural instability.  Cognitive decline consistent with dementia is also evident, impacting domains such as executive function, memory, visuospatial skills, and language.  Symptoms include difficulty with planning, problem-solving, recalling recent events, navigating familiar environments, and expressing thoughts fluently.  The patient meets the Movement Disorder Society clinical diagnostic criteria for probable Parkinson's disease and the DSM-5 criteria for major neurocognitive disorder due to Parkinson's disease.  Differential diagnoses considered included Lewy body dementia, Alzheimer's disease, and vascular dementia.  Assessment included a comprehensive neurological examination, cognitive testing such as the Montreal Cognitive Assessment (MoCA), and review of medical history.  The patient's current medication regimen includes carbidopa-levodopa for motor symptom management.  A cholinesterase inhibitor is being considered for cognitive symptoms.  Further evaluation may include neuroimaging such as DaTscan to aid in differentiating Parkinsonian syndromes.  The patient's functional status is declining, impacting activities of daily living (ADLs) such as dressing, bathing, and eating.  Caregiver support and education regarding disease progression, medication management, and safety precautions were provided.  Prognosis and treatment options were discussed with the patient and family.  Follow-up appointments are scheduled to monitor disease progression and adjust treatment as needed.